In which adult patients is a rectal fecal‑management tube indicated, what are the contraindications, and how should it be inserted, secured, and managed?

Rectal Fecal Management Tubes in Adult Patients

Rectal fecal management systems (FMS) should be used selectively in hospitalized adults with severe diarrhea and fecal incontinence when skin protection or infection control is critical, but only for short durations (ideally <17 days) due to significant complication risks including lower GI bleeding, vaginal perforation, and anal atony.

Indications for Use

Rectal tubes are indicated in the following clinical scenarios:

• Severe diarrhea with fecal incontinence requiring skin protection from perineal dermatitis 1
• Prevention of nosocomial infection transmission in acute and critical care settings 1
• Protection of perineal wounds including pressure ulcers, burn injuries, and necrotizing fasciitis 2
• Temporary fecal diversion as an alternative to colostomy in Fournier's gangrene when sphincter involvement is limited, though this should be restricted to short periods to avoid intra-rectal device damage 3

The device is most commonly used in ICU patients with excessive bowel motions, though these patients have substantially higher mortality (15% vs 7.7%) and longer ICU stays, reflecting their underlying severity of illness 4.

Absolute Contraindications

Do not use rectal tubes in patients with:

• Anal stenosis
• Acute intestinal obstruction or perforation 5
• Rectal malignant tumors 5
• Coagulopathy, thrombocytopenia, or active GI bleeding 5, 6
• Recent colorectal surgery with fresh anastomosis (unless specifically placed trans-anastomotically by the surgeon)

Relative Contraindications and High-Risk Populations

Exercise extreme caution or avoid use in:

• Female patients, particularly those with tissue fragility, as vaginal perforations have been reported even after 4 days of use 6
• Disseminated intravascular coagulation (DIC) - vaginal perforation occurred after only 4 days in one case 6
• Severe underlying cardiopulmonary disease 5
• Critically ill patients with impaired tissue integrity 6

Insertion and Management Protocol

Device Selection and Insertion

• Use a flexible silicone catheter with retention balloon (Flexi-Seal or similar FMS)
• Most commonly, a Foley catheter is adapted for this purpose 7
• Position patient in left lateral decubitus position with knees flexed 5
• Lubricate thoroughly with liquid paraffin or water-soluble lubricant
• Insert slowly with gentle rotation, monitoring for resistance
• Inflate retention balloon per manufacturer specifications - avoid overinflation (occurred in 14% of cases in one series) 2

Securing and Monitoring

• Secure externally to prevent migration
• Check balloon inflation daily to prevent overinflation complications 2
• Monitor for stool leakage around device
• Assess anal sphincter tone regularly - temporary anal atony occurred in 8% of patients 2

Duration Limits

• Optimal duration: <17 days 2
• Maximum recommended duration: 29 days 1
• Complication rates increase significantly with longer duration (44% for ≥17 days vs 15% for <17 days, p=0.024) 2
• Median actual use: 5 days (range 1-23 days) 4

Serious Complications to Monitor

Major adverse events occur in approximately 3% of patients (0.5 events per 100 device-days) 4:

• Lower GI bleeding requiring 2-23 units of packed red blood cells 4
• Rectal perforation requiring laparotomy 4
• Vaginal perforation with rectovaginal fistula formation, particularly in critically ill women 6
• Temporary anal atony (8% of cases) 2
• Mucosal injury from balloon overinflation 2

Minor complications include:

• Excessive stool leakage around device (4%) 2
• Patient discomfort, pain, or burning (uncommon) 1
• Palpitations and sweating during insertion (14.3%) 5

Clinical Pitfalls to Avoid

1. Do not overinflate the retention balloon - this was the most common complication (14% of cases) 2
2. Do not use for extended periods - risk doubles after 17 days 2
3. Screen carefully for coagulopathy in critically ill patients, especially those with DIC 6
4. Monitor female patients more closely for vaginal perforation, particularly if tissue integrity is compromised 6
5. Do not use as routine practice - reserve for cases where benefits clearly outweigh risks 4
6. Reassess indication daily - remove as soon as diarrhea resolves or skin protection is no longer critical

Efficacy Outcomes

When used appropriately:

• Skin condition improved or maintained in >92% of patients 1
• 100% success rate for acute fecal impaction management 5
• Rectal mucosa remained healthy on endoscopic evaluation after device removal 1
• Clinicians reported the system was practical, time-efficient, and improved fecal incontinence management 1